Atherosclerosis and rheumatoid arthritis

More than a simple association

Lorenzo Cavagna, Nicola Boffini, Giovanni Cagnotto, Flora Inverardi, Vittorio Grosso, Roberto Caporali

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

In the last decades a large amount of evidence linked rheumatoid arthritis (RA) to atherosclerosis. In fact, RA patients have an increased risk of cardiovascular events that is not fully explained by other classic cardiovascular risk factors. RA and atherosclerosis may share several common pathomechanisms and inflammation undoubtedly plays a primary role. The proinflammatory cytokines such as tumor necrosis factor alpha and interleukin-6, involved in the pathogenesis of RA, are also independently predictive of subsequent cardiovascular disease (CVD). In RA, inflammation alters HDL constituents and the concentration of LDL and HDL, thus facilitating atherosclerosis and CVD events. On the other hand, also the increase of oxidative processes, frequently observed in RA, induces atherosclerosis. Interestingly, some genetic polymorphisms associated with RA occurrence enhance atherosclerosis, however, other polymorphisms associated with RA susceptibility do not increase CVD risk. Several other mechanisms may influence atherosclerotic processes in RA. Moreover, atherosclerosis may be directly mediated also by underlying autoimmune processes, and indirectly by the occurrence of metabolic syndrome and impaired physical activity. Finally, the effects of RA therapies on cardiovascular system in general and on atherosclerosis in particular are really wide and different. However, the starting point of every RA treatment is that disease control, or better remission, is the best way we have for the reduction of CVD occurrence.

Original languageEnglish
Article number147354
JournalMediators of Inflammation
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Rheumatoid Arthritis
Atherosclerosis
Cardiovascular Diseases
Inflammation
Genetic Polymorphisms
Cardiovascular System
Interleukin-6
Tumor Necrosis Factor-alpha
Exercise
Cytokines
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Atherosclerosis and rheumatoid arthritis : More than a simple association. / Cavagna, Lorenzo; Boffini, Nicola; Cagnotto, Giovanni; Inverardi, Flora; Grosso, Vittorio; Caporali, Roberto.

In: Mediators of Inflammation, Vol. 2012, 147354, 2012.

Research output: Contribution to journalArticle

Cavagna, Lorenzo ; Boffini, Nicola ; Cagnotto, Giovanni ; Inverardi, Flora ; Grosso, Vittorio ; Caporali, Roberto. / Atherosclerosis and rheumatoid arthritis : More than a simple association. In: Mediators of Inflammation. 2012 ; Vol. 2012.
@article{91ab99ce0b2b469caf2a9cced8097135,
title = "Atherosclerosis and rheumatoid arthritis: More than a simple association",
abstract = "In the last decades a large amount of evidence linked rheumatoid arthritis (RA) to atherosclerosis. In fact, RA patients have an increased risk of cardiovascular events that is not fully explained by other classic cardiovascular risk factors. RA and atherosclerosis may share several common pathomechanisms and inflammation undoubtedly plays a primary role. The proinflammatory cytokines such as tumor necrosis factor alpha and interleukin-6, involved in the pathogenesis of RA, are also independently predictive of subsequent cardiovascular disease (CVD). In RA, inflammation alters HDL constituents and the concentration of LDL and HDL, thus facilitating atherosclerosis and CVD events. On the other hand, also the increase of oxidative processes, frequently observed in RA, induces atherosclerosis. Interestingly, some genetic polymorphisms associated with RA occurrence enhance atherosclerosis, however, other polymorphisms associated with RA susceptibility do not increase CVD risk. Several other mechanisms may influence atherosclerotic processes in RA. Moreover, atherosclerosis may be directly mediated also by underlying autoimmune processes, and indirectly by the occurrence of metabolic syndrome and impaired physical activity. Finally, the effects of RA therapies on cardiovascular system in general and on atherosclerosis in particular are really wide and different. However, the starting point of every RA treatment is that disease control, or better remission, is the best way we have for the reduction of CVD occurrence.",
author = "Lorenzo Cavagna and Nicola Boffini and Giovanni Cagnotto and Flora Inverardi and Vittorio Grosso and Roberto Caporali",
year = "2012",
doi = "10.1155/2012/147354",
language = "English",
volume = "2012",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Atherosclerosis and rheumatoid arthritis

T2 - More than a simple association

AU - Cavagna, Lorenzo

AU - Boffini, Nicola

AU - Cagnotto, Giovanni

AU - Inverardi, Flora

AU - Grosso, Vittorio

AU - Caporali, Roberto

PY - 2012

Y1 - 2012

N2 - In the last decades a large amount of evidence linked rheumatoid arthritis (RA) to atherosclerosis. In fact, RA patients have an increased risk of cardiovascular events that is not fully explained by other classic cardiovascular risk factors. RA and atherosclerosis may share several common pathomechanisms and inflammation undoubtedly plays a primary role. The proinflammatory cytokines such as tumor necrosis factor alpha and interleukin-6, involved in the pathogenesis of RA, are also independently predictive of subsequent cardiovascular disease (CVD). In RA, inflammation alters HDL constituents and the concentration of LDL and HDL, thus facilitating atherosclerosis and CVD events. On the other hand, also the increase of oxidative processes, frequently observed in RA, induces atherosclerosis. Interestingly, some genetic polymorphisms associated with RA occurrence enhance atherosclerosis, however, other polymorphisms associated with RA susceptibility do not increase CVD risk. Several other mechanisms may influence atherosclerotic processes in RA. Moreover, atherosclerosis may be directly mediated also by underlying autoimmune processes, and indirectly by the occurrence of metabolic syndrome and impaired physical activity. Finally, the effects of RA therapies on cardiovascular system in general and on atherosclerosis in particular are really wide and different. However, the starting point of every RA treatment is that disease control, or better remission, is the best way we have for the reduction of CVD occurrence.

AB - In the last decades a large amount of evidence linked rheumatoid arthritis (RA) to atherosclerosis. In fact, RA patients have an increased risk of cardiovascular events that is not fully explained by other classic cardiovascular risk factors. RA and atherosclerosis may share several common pathomechanisms and inflammation undoubtedly plays a primary role. The proinflammatory cytokines such as tumor necrosis factor alpha and interleukin-6, involved in the pathogenesis of RA, are also independently predictive of subsequent cardiovascular disease (CVD). In RA, inflammation alters HDL constituents and the concentration of LDL and HDL, thus facilitating atherosclerosis and CVD events. On the other hand, also the increase of oxidative processes, frequently observed in RA, induces atherosclerosis. Interestingly, some genetic polymorphisms associated with RA occurrence enhance atherosclerosis, however, other polymorphisms associated with RA susceptibility do not increase CVD risk. Several other mechanisms may influence atherosclerotic processes in RA. Moreover, atherosclerosis may be directly mediated also by underlying autoimmune processes, and indirectly by the occurrence of metabolic syndrome and impaired physical activity. Finally, the effects of RA therapies on cardiovascular system in general and on atherosclerosis in particular are really wide and different. However, the starting point of every RA treatment is that disease control, or better remission, is the best way we have for the reduction of CVD occurrence.

UR - http://www.scopus.com/inward/record.url?scp=84867790335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867790335&partnerID=8YFLogxK

U2 - 10.1155/2012/147354

DO - 10.1155/2012/147354

M3 - Article

VL - 2012

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 147354

ER -